Showing 341 - 360 results of 19,052 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 10 ((nm decrease) OR (nn decrease)) ))', query time: 0.53s Refine Results
  1. 341
  2. 342

    Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

    Published 2020
    “…<b>(e)</b> A tentative timeline of the neural processing of the audiovisual speech in -50 to 250 ms around the sound onset. …”
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
  14. 354

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
  15. 355

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
  16. 356

    Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

    Published 2025
    “…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC<sub>50</sub> = 0.1 nM, msEH IC<sub>50</sub> = 0.1 nM). …”
  17. 357
  18. 358

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  19. 359

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  20. 360

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”